Grant: Team Grant: E-Rare Joint Transnational Call
Ottawa Hospital Research Institute
$300,000.00
A multidimensional single-cell approach to understand muscle dystrophy
EF 2019-20
Résumé
Duchenne Muscular Dystrophy (DMD) and LAMA2-related Muscular Dystrophy (LAMA2 MD) are rare and devastating genetic disease of childhood manifested by progressive skeletal muscle wasting and ultimately death. In both diseases, muscle undergoes constant cycles of degeneration-regeneration exacerbated by intrinsic muscle stem cell (MuSC) dysfunction and their impaired ability to support long-term regeneration. The overall goal of the project is to use a combination of single-cell transcriptomics (RNA-sequencing) and proteomics (mass cytometry, CyTOF) to define the cellular composition of diseased muscle tissues at the single-cell resolution. We will delineate the different cell populations that pre-exist and arise during disease progression and classify the novel cellular subsets involved in this process. This data, in combination with genetic lineage tracing will allow reconstruction of the MuSC lineage hierarchy. We will further characterize cellular subpopulations associated with human muscle dystrophies by performing 3-Dimensional intact-tissue RNA sequencing on patient biopsies The unbiased elucidation of the cellular events underlying the different steps of muscle disease progression at the single-cell level represents crucial missing information, which will push forward our current knowledge on muscle dystrophies. Ultimately, our goal is to develop new biomarkers and eventually new pharmacological approaches to enhance therapy by stimulating intrinsic muscle tissue repair and capitalize on our single cell expertise to uncover disease-related subsets in human biopsies.
Programme
Team Grant: E-Rare Joint Transnational Call
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406644
Name
Rudnicki Michael A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Muscular Dystrophy Canada, Quebec Regional Office (Montreal); The French National Research Agency (France); Ministero della Salute (Italy); Swiss National Science Foundation (Switzerland)
Instname2
Genetics
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
A multidimensional single-cell approach to understand muscle dystrophy
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Biomarkers; Duchenne Muscular Dystrophy; Lama2-Related Muscular Dystrophy; Muscle Stem Cell; Single Cell Proteomics; Single Cell Transcriptomics
Abstract
Duchenne Muscular Dystrophy (DMD) and LAMA2-related Muscular Dystrophy (LAMA2 MD) are rare and devastating genetic disease of childhood manifested by progressive skeletal muscle wasting and ultimately death. In both diseases, muscle undergoes constant cycles of degeneration-regeneration exacerbated by intrinsic muscle stem cell (MuSC) dysfunction and their impaired ability to support long-term regeneration. The overall goal of the project is to use a combination of single-cell transcriptomics (RNA-sequencing) and proteomics (mass cytometry, CyTOF) to define the cellular composition of diseased muscle tissues at the single-cell resolution. We will delineate the different cell populations that pre-exist and arise during disease progression and classify the novel cellular subsets involved in this process. This data, in combination with genetic lineage tracing will allow reconstruction of the MuSC lineage hierarchy. We will further characterize cellular subpopulations associated with human muscle dystrophies by performing 3-Dimensional intact-tissue RNA sequencing on patient biopsies The unbiased elucidation of the cellular events underlying the different steps of muscle disease progression at the single-cell level represents crucial missing information, which will push forward our current knowledge on muscle dystrophies. Ultimately, our goal is to develop new biomarkers and eventually new pharmacological approaches to enhance therapy by stimulating intrinsic muscle tissue repair and capitalize on our single cell expertise to uncover disease-related subsets in human biopsies.
Competitiondate
201906
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rudnicki, Michael A
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $300,000~ $0~